Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NBP
STRONG SELLNovaBridge Biosciences · Healthcare · United States · $205M · Avg Vol: $1M/d
11
StockRankGet insider-trade alerts
Q
35
V
34
M
19
P/E (TTM)
—
ROE
-40.9%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
NovaBridge Biosciences is a biotechnology company focused on the discovery and development of novel therapeutic candidates, likely targeting specific diseases with unmet medical needs. The company's competitive position hinges on the innovation of its drug pipeline and the potential for its proprietary compounds to address significant medical challenges.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | -1.6M | 0.6M | 0 | 0 | — | — |
| EPS | -4.82 | -4.24 | -2.33 | -0.28 | -0.40 | — | -0.48 |
| Shares | — | 190.9M | 185.6M | 187.5M | 115.6M | -39.4% | 115.6M |
| Debt | — | 10.9M | 3.9M | 3.9M | 3.1M | -34.4% | 3.1M |
| Equity | — | 421.8M | 242.6M | 201.2M | 230.9M | -18.2% | — |
| Op CF | — | -49.6M | -72.7M | -52.7M | -20.6M | — | -20.6M |
| Inv CF | — | -5.2M | -15.2M | -136.0M | 105.0M | — | — |
| Fin CF | — | 3.9M | -8.2M | -0.3M | 57.7M | — | — |
Loading 1Y...
PRICE (1Y)+20.4%
SMA 50SMA 200
Close
$1.77
RSI (14)
30.0
52W High
$6.79
From 52W High
0.3%
SCORE BREAKDOWN
Quality
35
ROIC
-40.4%18.7
ROE
-40.9%21.7
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-7.9%31.5
Piotroski
321.7
Int. Cover
—N/A
D/E Ratio
0.01x82.6
Current Ratio
8.09x82.5
Value
34
P/E (TTM)
—N/A
EV/EBITDA
0.0x25.0
P/FCF
—N/A
P/B
0.9x87.1
P/S
—N/A
Div Yield
—N/A
Momentum
19
52W High %
26%5.9
RS 6M
-62%10.4
SMA 50/200
0.56x2.6
EPS Rev 4W
0.0%62.5
EPS Rev 12W
0.0%56.7
EPS Improve
-121%3.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$205M
P/E (Forward)
-1.7x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NBP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NBP | NovaBridge Biosciences(you) | $205M | 11 | STRONG SELL |
| TARA | Protara Therapeutics, Inc. | $226M | 12 | STRONG SELL |
| IVVD | Invivyd, Inc. | $180M | 12 | STRONG SELL |
| RNAC | Cartesian Therapeutics, Inc. | $232M | 12 | STRONG SELL |
| NAUT | Nautilus Biotechnology, Inc. | $215M | 14 | STRONG SELL |
| AVXL | Anavex Life Sciences Corp. | $222M | 9 | STRONG SELL |
| GALT | Galectin Therapeutics Inc. | $229M | 9 | STRONG SELL |
| GLSI | Greenwich LifeSciences, Inc. | $191M | 8 | STRONG SELL |
| TRDA | Entrada Therapeutics, Inc. | $227M | 8 | STRONG SELL |
| PYXS | Pyxis Oncology, Inc. | $165M | 13 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.6%